Breaking News

Teva, Blackstone Life Sciences Enter $400M Funding Agreement for Duvakitug

Duvakitug is currently in phase 3 trials for ulcerative colitis and Crohn’s disease.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., and funds managed by Blackstone Life Sciences, entered a $400 million strategic funding agreement spread across four years to support the clinical development of duvakitug. Under the terms of the agreement, Blackstone will be eligible for regulatory and commercial milestones as well as royalties on duvakitug worldwide sales. Duvakitug is a human monoclonal antibody targeting TL1A, a target with the potential for br...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters